Column about China
China: Preferential policies related to drug application registration by using Real-World Evidence (RWE) in Hainan Medical Pilot
The National Medical Products Administration in China is actively exploring the use of clinical real-world evidence (RWE) data for medical device product registration.
- Medical Equipment
- New Trends
Change in China’s Regulatory Affairs
In November 2018, the Chinese State Medical Insurance Administration officially announced a trial plan for centralized drug procurement, the so-called “4+7 Plan”. We will check out what this policy and other changes in China's changing pharmaceutical regulations have in store for foreign innovators.